- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07557914
Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
A Multicenter, Prospective, Single-arm Clinical Study Evaluating the Efficacy and Safety of Epalrestat Combined With Hepatic Arterial Chemotherapy Infusion (HAIC), Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable Hepatocellular Carcinoma and Diabetes
The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
Contacten en locaties
Studiecontact
- Naam: Hongbin Zou
- Telefoonnummer: +8618040026871
- E-mail: hongbinzou300@gmail.com
Studie Locaties
-
-
Heilongjiang
-
Harbin, Heilongjiang, China, 150085
- Nog niet aan het werven
- Harbin Medical University Cancer Hospital
-
Contact:
- Dongfeng He
- Telefoonnummer: 18040026871
- E-mail: 2919534184@qq.com
-
-
Jilin
-
Yanji, Jilin, China, 133000
- Werving
- Yanbian University Hospital
-
Contact:
- Songnan Zhang
- Telefoonnummer: 18040026871
- E-mail: 2919534184@qq.com
-
-
Liaoning
-
Shenyang, Liaoning, China, 110000
- Actief, niet wervend
- The First Hospital of China Medical University
-
Shenyang, Liaoning, China, 110001
- Nog niet aan het werven
- Liaoning Cancer Hospital
-
Contact:
- Wenheng Zheng
- Telefoonnummer: 18040026871
- E-mail: 2919534184@qq.com
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Diabetes mellitus combined with unresectable advanced HCC (BCLC stage C);
- Patients who have the need for treatment, prevention and improvement of diabetic neuropathy;
- Liver function at Child-Pugh grade A or B (≤ 7 points), ECOG PS 0-1;
- Age 18-80 years old. Confirmed as unrectable HCC through pathological or imaging diagnosis;
Exclusion Criteria:
- Severe liver dysfunction: Child-Pugh C grade (≥ 8 points) or active hepatic encephalopathy Illness;
- Extensive extrahepatic metastases (e.g., lung, bone, or peritoneum metastases);
- Severe cardiovascular diseases: Uncontrolled heart failure, recent myocardial infarction;
- Renal failure: Creatinine clearance rate < 30 mL/min;
- Thrombocytopenia (less than 50×10⁹/L) or coagulation dysfunction (INR greater than 1.5);
- Active infection (such as uncontrolled hepatitis B virus replication with HBV-DNA > 2000 IU/mL);
- ECOG PS ≥ 2 or extremely poor overall condition;
- Diabetic patients with acute ketoacidosis or during the period of severe infection;
- Pregnant and lactating women;
- Known history of other malignancy.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Epalrestat plus HAIC, donafenib and tislelizumab
Epalrestat 50mg tid, donafenib 0.2g bid, tislelizumab 200mg per 21days, HAIC (FOLFOX or RALOX) per 21days |
For the first 6 patients in the safety lead-in period, the starting dose of epalrestat was 50 mg, three times per day. If dose-limiting toxicity (DLT) occurred in the first 6 patients, the dose for the second round of 6 patients in the safety lead-in period would be adjusted to 50 mg, twice per day. If DLT occurred in the second round of 6 patients, the dose for the third round of 6 patients in the safety lead-in period would be adjusted to 50 mg, once per day. donafenib 0.2g BID, tislelizumab 200mg/21days Include FOLFOX and RALOX.
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
12-month Event-free survival (EFS) Rate
Tijdsspanne: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
The proportion of patients who have remained event-free from the start of treatment until the 12-month time point.(Predefined events include: progression of disease, death for any reason, terminate the treatment due to intolerable AEs.) |
From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Event-free survival (EFS)
Tijdsspanne: From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
Defined as the time from treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs). |
From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
|
Overall survival (OS)
Tijdsspanne: Up to approximately 2 years
|
The OS is defined as the time from the enrollment to death due to any cause. |
Up to approximately 2 years
|
|
Progression free survival(PFS) (Overall)
Tijdsspanne: From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented progressive disease (according to mRECIST) or death due to any cause, whichever occurs first. |
From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.
|
|
Progression free survival(PFS) of intra-hepatic lesions
Tijdsspanne: From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, whichever occurs first. |
From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.
|
|
Progression free survival(PFS) of extra-hepatic lesions
Tijdsspanne: From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, whichever occurs first. |
From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.
|
|
Objective response rate(ORR) per RESCIST 1.1
Tijdsspanne: Up to approximately 2 years
|
The ORR is defined as the proportion of patients with a documented complete response(CR) or partial response(PR) per RECIST 1.1. |
Up to approximately 2 years
|
|
ORR per mRECIST
Tijdsspanne: Up to approximately 2 years
|
The ORR is defined as the proportion of patients with a documented CR or PR per mRECIST. |
Up to approximately 2 years
|
|
PVTT response rate per mRECIST
Tijdsspanne: Up to approximately 2 years
|
The PVTT response rate is defined as the proportion of patients with a documented CR or PR of PVTT. According to the Vp classification: CR: PVTT disappears or the portal vein becomes completely unobstructed. PR: Decrease in VP classification. SD: Without PR and PD. PD: Increase in VP classification. |
Up to approximately 2 years
|
|
Disease control rate(DCR) per RESCIST 1.1
Tijdsspanne: Up to approximately 2 years
|
The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per RECIST 1.1. |
Up to approximately 2 years
|
|
DCR per mRECIST
Tijdsspanne: Up to approximately 2 years
|
The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per mRECIST. |
Up to approximately 2 years
|
|
Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0
Tijdsspanne: Up to approximately 2 years
|
The percentage and degree of patients who experience at least one AE, whether or not considered related to the treatment, according to CTCAE version 5.0. |
Up to approximately 2 years
|
Medewerkers en onderzoekers
Sponsor
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Haibo Shao, First Hospital of China Medical University
- Hoofdonderzoeker: Tao Han, First Hospital of China Medical University
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Endocriene systeemziekten
- Neoplasmata per site
- Neoplasmata
- Metabole ziekten
- Neoplasmata per histologisch type
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Glucosemetabolismestoornissen
- Lever Ziekten
- Neoplasmata, glandulair en epitheel
- Adenocarcinoom
- Lever neoplasmata
- Carcinoom
- Voedings- en stofwisselingsziekten
- Carcinoom, hepatocellulair
- Suikerziekte
- tislelizumab
- donafenib
- Epalrestat
Andere studie-ID-nummers
- kelunshen【2025】2025-861-2
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Consent and privacy: Participants usually only agreed to data use in the original study. Sharing IPD may violate that agreement. And we want to protect our academic credit and avoid misuse of the data.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .